FDA Approves First New Sunscreen Ingredient in 25 Years: Bemotrizinol

The U.S. Food and Drug Administration (FDA) has approved bemotrizinol, a sunscreen ingredient that has been available in Europe and other regions for decades, as the first new active component in the American market in over 25 years. This development marks a significant step in updating U.S. sunscreen technology, which has lagged behind global advancements due to bureaucratic delays in regulatory approvals.

What’s claimed: Bemotrizinol is marketed as a broad-spectrum sunscreen agent that protects against both ultraviolet A (UVA) and ultraviolet B (UVB) rays without leaving the white residue associated with mineral-based ingredients like zinc oxide. The FDA states it causes minimal skin irritation and is safe for use by adults and children as young as 6 months.

What’s actually new: The approval of bemotrizinol is notable not just for the ingredient itself but for the regulatory pathway that enabled it. Congress authorized a streamlined process in 2020 to expedite the review of certain ingredients, which the FDA used to evaluate bemotrizinol. This contrasts with the agency’s traditional, lengthy process for adding new sunscreen components, which has stalled innovation for decades. The ingredient was first filed with the FDA in 2005 but faced prolonged delays before gaining approval.

Limitations: While bemotrizinol offers a promising alternative, its initial availability will be limited to a single manufacturer, DSM Nutritional Products, under the brand name Parsol Shield. This exclusivity period lasts 18 months, after which other companies may adopt the ingredient. Additionally, long-term safety data remains limited, as the FDA’s approval was based on existing studies rather than new trials. Critics also note that the ingredient does not address other sunscreen challenges, such as photostability or performance under prolonged UV exposure.

The approval underscores a broader shift in FDA policy. In 2011, the agency banned misleading terms like "waterproof" and mandated UVA and UVB protection in all sunscreens. However, progress has been slow, with proposed rules from 2021—including stricter SPF limits and enhanced UVA protection—still pending. Bemotrizinol’s approval fills a specific gap: many chemical sunscreens currently protect against only one type of UV ray, requiring combinations to achieve broad-spectrum coverage. Mineral-based options, while effective, often leave a chalky residue that some users find uncomfortable.

Experts highlight the significance of this approval. David Andrews of the Environmental Working Group (EWG) called it a "critical step" in modernizing U.S. sunscreen standards, which have historically prioritized UVB protection over UVA. The EWG has long advocated for stricter regulations and faster approval of new ingredients. "For decades, Americans have used outdated sunscreen tech while the rest of the world moved forward," Andrews said. "The approval of bemotrizinol will help change that."

Despite its potential, bemotrizinol is not a panacea. It will initially be available only in Parsol Shield products, which may limit consumer access. Additionally, while it avoids the white residue of zinc oxide, it is a chemical filter, raising questions about long-term skin absorption and environmental impact. The FDA’s decision reflects a balance between innovation and caution, but it also highlights the need for continued regulatory reform to keep pace with scientific advancements.

For consumers, this approval offers a new option to consider, particularly for those seeking broad-spectrum protection without the drawbacks of mineral-based formulas. However, experts advise consulting dermatologists for personalized recommendations and emphasizing the importance of reapplying sunscreen regularly, regardless of the ingredient used.

Key links:

• DSM Nutritional Products (Parsol Shield)
• Environmental Working Group’s sunscreen guide
• FDA’s sunscreen regulatory page